A quest for further research into therapeutics focusing on glypicans could be to silence GPC6 as suggested by Yiu et al. (2011) to lower the metastatic ability and thus to improve the prognosis for RFS of breast cancer patients. The gene discussed is GPC1; the disease is breast carcinoma.